SRS advises C2 Capital on Bluepharma investment

SRS Legal has advised C2 Capital on the investment of 30 million euros in Bluepharma, becoming a reference shareholder in this pharmaceutical company.

The SRS Legal team responsible for advising was led by partner Gustavo Ordonhas Oliveira (pictured), including lawyers Marco Silva Garrinhas, Joana Ferreira Gonçalves, and involved a multidisciplinary team in carrying out legal due diligence on Bluepharma and drafting and negotiating investment contracts.

This partnership between C2 Capital and Bluepharma aims to provide a substantial financial boost to drive Bluepharma’s strategic projects over the next decade. The investment of 30 million euros aims to reinforce Bluepharma’s Research and Development (R&D) strategy, contributing to the industrial capacity of the pharmaceutical multinational based in Coimbra.

The investment will play a crucial role in the solid advancement of the “Coimbra Life Sciences Park” and CiNTech projects, within the scope of the PRR (Resilience and Recovery Plan). These projects aim to promote the creation and training of the first technological hub fully dedicated to complex injectable medicines in Portugal.

Michael Heron